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Objectives This study sought to investigate the efficacy and safety of clopidogrel in women and men.
Background Previous analyses have shown sex-based differences in response to several antiplatelet medications. Little is
known about the efficacy and safety of clopidogrel in women and men.
Methods This study performed a meta-analysis of all blinded randomized clinical trials comparing clopidogrel and placebo
(CURE [Clopidogrel in Unstable Angina to Prevent Recurrent Events], CREDO [Clopidogrel for the Reduction of
Events During Observation], CLARITY–TIMI 28 [Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In
Myocardial Infarction 28], COMMIT [Clopidogrel and Metoprolol in Myocardial Infarction Trial], and CHARISMA
[Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance] trials),
involving a total of 79,613 patients, of whom 30% were women. The relative efficacy and safety of clopidogrel
at reducing cardiovascular events (cardiovascular death, myocardial infarction [MI], or stroke) in women and
men was estimated using random-effects modeling.
Results Overall, clopidogrel was associated with a highly significant 14% proportional reduction in the risk of cardiovas-
cular events (odds ratio [OR]: 0.86; 95% confidence interval [CI]: 0.80 to 0.93), with no significant differences in
treatment effect between women and men. Among the 23,533 women enrolled, there were fewer cardiovascu-
lar events in the clopidogrel group compared with the placebo group (11.0% vs. 11.8%; OR: 0.93; 95% CI: 0.86
to 1.01). In women the risk reduction with clopidogrel seemed to be greatest for MI (OR: 0.81; 95% CI: 0.70 to
0.93), with the effects on stroke (OR: 0.91; 95% CI: 0.69 to 1.21) or total death (OR: 0.99; 95% CI: 0.90 to 1.08)
not statistically significant. Among the 56,091 men enrolled, there were fewer cardiovascular events in those
receiving clopidogrel compared with placebo (7.8% vs. 9.0%; OR: 0.84; 95% CI: 0.78 to 0.91), and the risk re-
duction was significant for MI (OR: 0.83; 95% CI: 0.76 to 0.92), stroke (OR: 0.83; 95% CI: 0.71 to 0.96), and to-
tal death (OR: 0.91; 95% CI: 0.84 to 0.97). Clopidogrel increased the risk of major bleeding in both women (OR:
1.43; 95% CI: 1.15 to 1.79) and men (OR: 1.22; 95% CI: 1.05 to 1.42).
Conclusions Clopidogrel reduces the risk of cardiovascular events in both women and men. (J Am Coll Cardiol 2009;54:
1935–45) © 2009 by the American College of Cardiology Foundation
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Clopidogrel and Sex November 17, 2009:1935–45Pathological and clinical studies
consistently show the importance
of platelets in the pathogenesis of
atherosclerosis and coronary
thrombosis (1–5). Medications
aimed at disrupting platelet ac-
tivity have been shown to reduce
cardiovascular morbidity and
mortality in a variety of settings
6–8). However, several studies showed a sex-specific re-
ponse to several antiplatelet medications (9–13).
See page 1946
It has been previously shown that the response to aspirin
or the primary prevention of cardiovascular disease is
ifferent between women and men (9). Although a similar
rotection from cardiovascular events was noted, women
erived most of their benefit from a reduction in the risk of
troke, whereas men derived most of their benefit from a
eduction in the risk of myocardial infarction (MI). The
esponse to another antiplatelet medication, glycoprotein
Ib/IIIa inhibitors, was shown to have a sex-specific re-
ponse as well (10). However, there are very few data on the
ffect of clopidogrel in men versus women, even though it is
ne of the most frequently prescribed drugs.
Several randomized trials have evaluated the effect of
lopidogrel on cardiovascular events across a broad spectrum
f coronary disease (14–20). Accordingly, the most recent
cute coronary syndrome (ACS) guidelines make clopi-
ogrel treatment a class I recommendation with grade A
vidence in several different clinical situations (21–23).
nfortunately, many of the clinical trials did not include an
dequate number of women to determine whether the
enefits were similar in men and women. Trials that did
eport results in women reported aggregate events (e.g.,
ajor cardiovascular events), but did not report specific
utcomes such as death, MI, or stroke separately. Ex vivo
ssessment of the antiplatelet effect of clopidogrel suggests
hat women are more likely to be hyporesponsive to clopi-
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Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
MI  myocardial infarction
OR  odds ratioManuscript received December 2, 2008; revised manuscript received May 11, 2009,
ccepted May 26, 2009.ogrel than men (24), suggesting a potential clinical differ-
nce in the effectiveness of clopidogrel according to sex.
Accordingly, to better understand the impact of sex on
he response to clopidogrel, we performed a sex-specific
ollaborative meta-analysis of clopidogrel therapy for the
revention of cardiovascular events.
ethods
iterature search. This meta-analysis considered random-
zed clinical trials comparing clopidogrel in combination
ith aspirin to aspirin alone for the treatment of patients at
igh risk for cardiovascular events. Comprehensive searches
f the Medline and Cochrane Central Register of Con-
rolled Trials databases were performed using Internet-
ased engines (PubMed and OVID) for studies published
etween 1999 and May 2007. Search terms included clopi-
ogrel, cardiovascular disease, MI, stroke, percutaneous
oronary intervention, and randomized controlled trials, as
ell as combinations of these terms. Experts in the field
ere questioned, bibliographies of retrieved articles were
earched for other relevant studies, and major scientific
eetings were monitored.
tudy selection. Trials that met the following criteria were
ncluded: 1) prospective, randomized, placebo controlled,
pen or blinded trials; 2) assignment of participants to
lopidogrel treatment and a placebo group; and 3) data on
ll-cause mortality, cardiovascular death, MI, stroke, and
ajor bleeding. A total of 197 potentially eligible studies
ere identified, and 131 were excluded based on title and
bstract for not fulfilling inclusion criteria on the basis of
ntervention. On further review, 61 studies were excluded
ither because of their nonrandomized nature or because
hey were not placebo controlled (Fig. 1).
utcomes measures. The clinical end point definitions
ere similar among the trials. Outcomes examined in the
urrent overview were a composite end point of any majorFigure 1 Flow Diagram of the Trial Selection Process
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November 17, 2009:1935–45 Clopidogrel and Sexardiovascular event (cardiovascular mortality, nonfatal MI,
r nonfatal stroke), MI (fatal and nonfatal), stroke (fatal and
onfatal), cardiovascular mortality, and all-cause mortality.
n the COMMIT (Clopidogrel and Metoprolol in Myo-
ardial Infarction Trial) (17), the composite end point
ncluded all-cause mortality rather than cardiovascular mor-
ality. We also examined the type of stroke (ischemic vs.
emorrhagic) in all 5 studies. The safety outcome examined
as the occurrence of major bleeding as defined by each
tudy.
tatistical analysis. For this collaborative meta-analysis,
he principal investigators of each of the included trials
upervised the extraction and verified the accuracy of the
ata from the databases of each trial. Sex-specific data from
ach trial, which have not been previously published, were
ombined for this study. The statistical analysis was per-
ormed using Stata Statistical Software, release 10 (Stata-
orp, College Station, Texas). Data were analyzed accord-
ng to the intention-to-treat principle. The Cochrane Q
tatistic was calculated to assess heterogeneity among the
rials for both men and women. However, because the lack
f heterogeneity does not necessarily imply homogeneity, a
ummary odds ratio (OR) was calculated using a random-
ffects model from the ORs and the 95% confidence
ntervals (CIs) for each end point in each study using
antel-Haenszel methods. To test for differences between
en and women for each end point, we used a formal test
or heterogeneity that is based on the Cochrane Q statistic
25). This test evaluates the degree to which overall heter-
geneity can be explained by heterogeneity between sub-
roups (25). If the p value for the test of heterogeneity is
ignificant (p  0.05), it suggests that the treatment effect
iffers between groups. In addition, we investigated differ-
nces between subgroups using metaregression to explore
he relationship between sex and the pooled value for each
esign of Trials Included in the Meta-AnalysisTable 1 Design of Trials Included in the Meta-Analysis
Trial, Year n Patient Population
Female Se
(%)
CURE, 2001 12,562 Patients who presented with acute
coronary syndromes without
ST-segment elevation
38.5
CREDO, 2003 2,116 Patients referred for a planned PCI
or coronary angiogram
28.6
CLARITY–TIMI 28,
2005
3,491 Patients who presented within
12 h after the onset of an
ST-segment elevation MI
19.7
COMMIT, 2005 45,852 Patients who presented within
24 h of suspected acute MI
27.8
CHARISMA, 2006 15,603 Patients with clinically evident
cardiovascular disease or
multiple risk factors
29.8
Both groups received 75mg/day of clopidogrel through day 28. †For patients who did not undergo
ame first.
CHARISMA  Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Managem
yocardial Infarction 28; COMMIT Clopidogrel and Metoprolol in Myocardial Infarction Trial; CREDO C
o Prevent Recurrent Events; MI  myocardial infarction; PCI  percutaneous coronary intervention.utcome measure. The results were nearly identical for each
utcome.
The statistical rationale for combining the data has been
reviously described and used extensively (26). Briefly, the
asic principle is that patients allocated to an intervention in
specific trial are only compared with those allocated to the
ontrol treatment in the same trial, avoiding direct compar-
sons of patients across different trials with different designs
nd lengths of follow-up. These methods provide for
ombination of information from multiple 2  2 tables,
enerating a summary OR and its 95% CI as reviewed by
antel and Haenszel (27) and modified by Yusuf et al. (28).
he data were also analyzed using a random-effects model
o generate relative risks and 95% CIs. These results did not
ualitatively differ from the primary analysis. A value of p
.05 was judged as statistically significant. Sensitivity anal-
ses were performed for each outcome to assess the contri-
ution of each study to the pooled estimate by excluding
ndividual trials one at a time and recalculating the com-
ined OR for the remaining studies. To assess publication
ias, we generated a funnel plot of the logarithm of effect
ize and compared it with the SE for each trial.
esults
earch results. We identified 5 randomized controlled
rials for inclusion (16–20). Women constituted between
0% and 39% of patients enrolled in the trials. In total,
9,613 individuals were enrolled in the 5 trials, of whom
3,522 (30%) were women.
Details of the included studies are shown in Table 1. A
road spectrum of cardiovascular disease was represented by
he 5 trials. The CURE (Clopidogrel in Unstable Angina to
revent Recurrent Events) trial (20) enrolled patients with a
Clopidogrel Dosage Clopidogrel Duration Follow-Up
300-mg loading dose
followed by
75 mg/day
3 to 12 months (mean
duration of treatment
9 months)
1 yr
300-mg loading dose
followed by 75 mg
once daily*
12 months 1 yr
300-mg loading dose
followed by 75 mg
once daily
Up to and including the day of
coronary angiography†
30 days
75 mg daily Hospital discharge or 28 days
(median of 2 weeks)
Hospital discharge or
28 days (median of
2 weeks)
75 mg daily Median of 28 months,
maximum of 35 months
Median of 28 months,
maximum of
35 months
aphy, study drug was to be administered up to and including day 8 or hospital discharge, whichever
Avoidance; CLARITY–TIMI 28  Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis Inx
angiogr
ent, and
lopidogrel for the Reduction of Events During Observation; CURE Clopidogrel in Unstable Angina
Characteristics of Women and Men Included in Trials of Clopidogrel Versus Placebo for the Prevention of Cardiovascular EventsTable 2 Characteristics of Women and Men Included in Trials of Clopidogrel Versus Placebo for the Prevention of Cardiovascular Events
CURE CREDO CLARITY COMMIT CHARISMA
Women Men Women Men Women Men Women Men Women Men
n 4,836 7,726 606 1,510 688 2,803 12,759 33,093 4,644 10,959
Demographics
Age (yrs) 66.5 10.7 62.7 11.4 64.4 10.6 60.6 11.0* 61.6 9.6 56.4 10.2* 66.6 9.7 59.3 11.9* 65.9 10.0 63.6 9.3*
Caucasians 82.4 81.8 85.6 90.1* 91.0 89.0 — — 89.1 91.0*
BMI (kg/m2) 27.5 4.5 27.4 3.8 30.0 6.4 30.1 7.4 27.7 5.4 27.4 4.0 — — 28.9 6.1 28.5 4.8
Clinical history
Current smoker 14.4 28.4 28.9 32.0 42.0 52.0* — — 17.6 21.3*
Hypertension — — 76.4 65.9* 56.0 41.0* 51.0 40.0* 81.5 70.2*
SBP (mm Hg) 137.2 132.4 135.0 21.4 132.6 19.9* 132.9 24.2 134.9 22.3 131.1 23.4 127.1 22.1 142.3 20.3 137.3 19.3
DBP (mm Hg) 77.3 76.7 70.1 11.9 74.8 11.8 77.9 14.7 81.5 14.1 81.0 14.4 80.9 14.5 79.0 11.2 78.8 10.7
Hyperlipidemia 48.4 44.5 77.4 76.3 37.0 39.0 — — 73.8 74.0
Diabetes 25.7 20.7 33.0 23.9* 20.0 16.0* — — 45.6 40.5*
Previous MI 25.7 36.2 28.4 37.4* 5.7 10.0* 6.6 9.0* 22.6 39.7*
CVD 59.4 59.3 8.1 5.2* — — — — 28.6 22.9*
PVD 6.9 9.2 9.8 8.0 4.4 4.1 — — — —
Previous CABG 7.4 13.2 11.8 18.1* — — — — 11.6 23.2*
Previous PCI 7.3 11.4 22.9 31.1* 2.0 5.6* — — 15.1 26.0*
Baseline medication use
Aspirin 66.3 66.0 28.1 30.5 14.1 16.1 18.2 18.5 90.1 93.7*
Values are presented as mean  SD or % unless otherwise indicated. *p  0.05.
BMI  body mass index; CABG  coronary artery bypass graft; CVD  cerebrovascular disease; DBP  diastolic blood pressure; PVD  peripheral vascular disease; SBP  systolic blood pressure; other abbreviations as in Table 1.
1938
Bergeretal.
JACC
Vol.54,No.21,2009
Clopidogreland
Sex
Novem
ber17,2009:1935–45
n
T
T
C
e
E
w
T
d
C
a
t
(
d
d
o
S
w
c
(
f
p
f
b
d
C
t
t
a
a
c
u
3
C
t
(
t
t
M
d
e
n
p
0
a
s
e
m
0
(
1939JACC Vol. 54, No. 21, 2009 Berger et al.
November 17, 2009:1935–45 Clopidogrel and Sexon–ST-segment elevation ACS, whereas the CLARITY–
IMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy–
hrombolysis In Myocardial Infarction 28) (18) and
OMMIT (17) trials enrolled patients with an ST-segment
levationMI. The CREDO (Clopidogrel for the Reduction of
vents During Observation) (19) trial enrolled patients in
hom a percutaneous coronary intervention was planned.
wo-thirds of the patients in the CREDO study had a
iagnosis of unstable angina or had suffered a recent MI. The
HARISMA (Clopidogrel for High Atherothrombotic Risk
nd Ischemic Stabilization,Management, and Avoidance) (16)
rial enrolled both patients with established vascular disease
80%) and patients with multiple risk factors for but without
ocumented vascular disease (20%). The weighted mean
uration of follow-up was 8.3 months. Baseline characteristics
f the individuals are presented in Table 2.
tudy quality. Randomized treatment allocation sequences
ere generated in all 5 studies. All 5 trials were placebo-
ontrolled and double-blinded. Treatment in the COMMIT
17) study was randomly assigned according to a 2  2
actorial design; patients were also assigned to metoprolol or
lacebo; this second randomization will not be considered
urther here. All 5 trials were partially or completely funded
y pharmaceutical companies that make or market clopi-
ogrel. Three of the trials were international (16,18,20), the
OMMIT trial was performed solely in China (17), and
Figure 2 Effect of Clopidogrel Treatment on the Effect of Major
Major cardiovascular events are defined as the composite of nonfatal myocardial i
effects model. Sizes of data markers are proportional to the amount of data contr
emic Stabilization, Management, and Avoidance; CI  confidence interval; CLARITY
Infarction 28; COMMIT  Clopidogrel and Metoprolol in Myocardial Infarction Trial;
dogrel in Unstable Angina to Prevent Recurrent Events; OR  odds ratio.he CREDO trial was performed in the U.S. (19). All 5
rials maintained independent clinical events committees to
djudicate the outcomes of interest blinded to treatment
ssignment. Three of the studies included a 300-mg
lopidogrel loading dose at study entry (18–20); all 5
sed a daily 75-mg dose of clopidogrel. Aspirin (75 to
25 mg/day in 4 trials and 75 to 162 mg/day in the
HARISMA trial) was administered to patients in all 5
rials. The duration of follow-up ranged from 2 weeks
the COMMIT trial) to 35 months (the CHARISMA
rial) and was more than 99% complete in each of the
rials.
ajor cardiovascular events. A total of 2,680 major car-
iovascular events occurred among the 23,533 women
nrolled in these trials (Fig. 2), with the event rate being
onsignificantly lower in women allocated clopidogrel com-
ared with those allocated placebo (11.0% vs. 11.8%; OR:
.93; 95% CI: 0.86 to 1.01).
A total of 4,704 major cardiovascular events occurred
mong the 56,091 men in these trials, and there was a highly
ignificant 16% reduction in the odds of cardiovascular
vents among men allocated clopidogrel compared with
en allocated placebo (7.8% vs. 9.0%; OR: 0.84; 95% CI:
.78 to 0.91). There was a weak trend for heterogeneity
p  0.092) that did not reach statistical significance
iovascular Events
on, nonfatal stroke, and cardiovascular death. Pooled ORs are from a random-
by each trial. CHARISMA  Clopidogrel for High Atherothrombotic Risk and Isch-
28  Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial
O  Clopidogrel for the Reduction of Events During Observation; CURE  Clopi-Card
nfarcti
ibuted
–TIMI
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Clopidogrel and Sex November 17, 2009:1935–45etween women and men for the outcome of major cardio-
ascular events.
ortality. Overall, there were 2,069 deaths in 23,522
omen (Fig. 3), and this risk was not significantly reduced
y allocation to clopidogrel in women (8.7% vs. 8.8%; OR:
.99; 95% CI: 0.90 to 1.08). Mode of mortality was
nalyzed in 4 of the 5 trials; no association was noted
etween clopidogrel allocation and cardiovascular mortality
OR: 1.04; 95% CI: 0.86 to 1.25).
A total of 3,197 deaths occurred in 56,091 men, and
llocation to clopidogrel produced a highly significant 9%
roportional reduction in the risk of all-cause mortality in
en (5.4% vs. 6.0%; OR: 0.91; 95% CI: 0.84 to 0.97). The
isk reduction for cardiovascular mortality was almost iden-
ical (OR: 0.92; 95% CI: 0.80 to 1.06), although the
eduction was not statistically significant. No evidence of
tatistical heterogeneity in pooled analyses between women
nd men was detected for all-cause mortality (p  0.158).
I. There were 766 MIs reported among the 23,533
omen (Fig. 4), with the rate being 2.9% in women
llocated clopidogrel compared with 3.6% in women allo-
ated placebo (OR: 0.81; 95% CI: 0.70 to 0.93). Each trial
eported a decreased risk of MI associated with clopidogrel
reatment when analyzed separately.
There were 1,729 MIs reported among the 56,091 men
nrolled, and the MI rate was 2.8% in the clopidogrel group
ompared with 3.4% in the placebo group (OR: 0.83; 95%
I: 0.76 to 0.92). As with women, each trial reported a
Figure 3 Effect of Clopidogrel Treatment on the Effect of All-Ca
Pooled ORs are from a random-effects model. Sizes of data markers are proportioecreased risk of MI associated with clopidogrel treatment. chere was no evidence of statistical heterogeneity in pooled
nalyses between women and men for MI (p  0.733).
troke. A total of 399 strokes occurred among women in
he 5 trials (Fig. 5), and the 9% proportional risk reduction
or total stoke with clopidogrel was not statistically signif-
cant (1.6% vs. 1.9%; OR: 0.91; 95% CI: 0.69 to 1.21), nor
ere the separate effects of clopidogrel on ischemic stroke
OR: 0.89; 95% CI: 0.71 to 1.12) or hemorrhagic stroke
1.2% vs. 1.4%; OR: 0.82; 95% CI: 0.29 to 2.32) among
omen.
A total of 739 strokes occurred among the men. There
as a significant decrease in the odds of stroke associated
ith clopidogrel (OR: 0.83; 95% CI: 0.71 to 0.96). When
ypes of stroke were analyzed separately, there was a
ignificant 16% reduction in ischemic stroke (OR: 0.84;
5% CI: 0.71 to 0.99), with no significant association with
emorrhagic stroke (OR: 0.95; 95% CI: 0.66 to 1.36).
here was no evidence of statistical heterogeneity in pooled
nalyses between women and men for stroke (p  0.552).
ajor bleeding. A total of 333 major bleeding events
ccurred among women (Fig. 6), with the odds being
ignificantly higher among women allocated clopidogrel
han among those allocated placebo (1.7% vs. 1.2%; OR:
.43; 95% CI: 1.15 to 1.79). Each trial reported an increased
isk of major bleeding associated with clopidogrel treatment.
Among the men there were a total of 683 major bleeding
vents recorded, and the rate was significantly higher among
en allocated clopidogrel than among men allocated pla-
Mortality
the amount of data contributed by each trial. Abbreviations as in Figure 2.use
nal toebo (1.3% vs. 1.1%; OR: 1.22; 95% CI: 1.05 to 1.42).
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November 17, 2009:1935–45 Clopidogrel and Sexhere was no evidence of statistical heterogeneity in pooled
nalyses between women and men for major bleeding (p 
.243).
ubgroup analysis. When patients enrolled with an ACS
the CURE, COMMIT, and CLARITY–TIMI 28 trials)
re analyzed separately, the efficacy and safety profile in
omen and men were similar to the results seen in the entire
tudy population (Table 3). In the CHARISMA trial,
lopidogrel was associated with an increase in adverse events
including death when analyzed separately) among patients
ithout established cardiovascular disease. We therefore
xcluded these patients (n  3,449) and evaluated the
enefit and risk of clopidogrel only among those with
stablished cardiovascular disease in the CHARISMA trial
nd the other 4 trials (Table 3). Once again, the efficacy and
afety profile in women and men is similar to the results
een in the entire population.
ensitivity analyses. Deletion of individual studies did not
ignificantly alter the primary outcome. A funnel plot of
ffect size versus study precision was symmetrical, consistent
ith a lack of major publication bias. There was no evidence
f statistical heterogeneity (as measured by both the Q-test
nd I2) between the trials for any of the end points
valuated.
iscussion
n this large study comparing the efficacy and safety of
Figure 4 Effect of Clopidogrel Treatment on the Effect of Myoc
Pooled ORs are from a random-effects model. Sizes of data markers are proportiolopidogrel versus placebo between women and men, we thow that clopidogrel reduced the risk of major cardiovas-
ular events in both women and men. In women, the overall
ffect of clopidogrel was driven by a reduction of MI. In
en, however, the effects of clopidogrel on MI, stroke, and
ll-cause mortality were separately significant. Despite these
bservations, there was no evidence of statistically signifi-
ant heterogeneity when the effect of clopidogrel was
ompared between women and men, indicating that much
f the difference between men and women could be ex-
lained by play of chance. Regarding major bleeding, there
ere small but real excess risks with clopidogrel therapy in
oth men and women.
enefit of clopidogrel therapy. Platelet inhibition remains
key component in the prevention and treatment of
schemic heart disease (6–8). Treatment with aspirin has
een shown to reduce cardiovascular morbidity and mortal-
ty in a wide variety of patients and clinical settings (29).
arge, randomized trials have shown improved outcomes
hen clopidogrel is added to aspirin across the spectrum of
ardiovascular disease (16–20). In a previous meta-analysis
30), clopidogrel was found to decrease cardiovascular mor-
idity and mortality. However, there had not previously
een a specific analysis of the efficacy and safety of clopi-
ogrel in women compared with men.
In this pooled sex-specific analysis, we found that clopi-
ogrel confers benefit in both women and men. We noted
n absolute risk reduction of 0.8% and 0.7% in women for
l Infarction
the amount of data contributed by each trial. Abbreviations as in Figure 2.ardia
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Clopidogrel and Sex November 17, 2009:1935–45ther words, an average duration of 8.3 months of treatment
ith clopidogrel results in an absolute benefit of approxi-
ately 8 cardiovascular events and 7 MIs prevented per
,000 women treated. Among women with ACS, we found
n absolute risk reduction of 0.9% in women for the
omposite end point, corresponding to 9 fewer cardiovas-
ular events per 1,000 women treated with clopidogrel. For
en, the absolute risk reduction for the composite and MI
nd point was 1.2% and 0.6%, respectively, corresponding to
pproximately 12 fewer cardiovascular events and 6 fewer
Is prevented per 1,000 men treated for an average of 8.3
onths. Among men with ACS, we found an absolute risk
eduction of 1.3% in men for the composite end point,
orresponding to 13 fewer cardiovascular events per 1,000
en treated with clopidogrel.
afety of clopidogrel therapy. Although effective in pre-
enting further thrombotic events, clopidogrel increases the
isk of bleeding. Adding clopidogrel to aspirin therapy
esulted in a 43% and 21% increased risk of major bleeding
n women and men, respectively. Based on the absolute
ncrease in bleeding of 0.5% and 0.2% in women and men,
espectively, the number needed to cause 1 major bleeding
vent (from an average treatment duration of 8.3 months)
ith clopidogrel was 200 women and 500 men. In other
ords, clopidogrel treatment over an average period of 8.3
onths results in an absolute increase of approximately 5
ajor bleeding events per 1,000 women and 2 major
Figure 5 Effect of Clopidogrel Treatment on the Effect of Strok
Pooled ORs are from a random-effects model. Sizes of data markers are proportioleeding events per 1,000 men. Among those with ACS, in rhom the bleeding risk is believed to be higher, the absolute
ncrease in major bleeding remained 0.5% for women and
.14% in men.
To better evaluate the balance of benefit versus risk in
oth groups, we provide the number needed to treat for each
ndividual end point and for a net clinical end point (MI,
troke, cardiovascular death, or major bleeding) in Table 4.
espite no significant difference between women and men,
here seems to be a greater benefit for clopidogrel in men.
o obtain net clinical benefit over a weighted mean
ollow-up of 8.3 months, one needed to treat 101 men
nd 435 women.
ex and antiplatelet medications. Several (9–13,31), al-
hough not all (32–34), previous studies have reported a
ex-specific response to antiplatelet medications. In a sex-
pecific meta-analysis of aspirin for the primary prevention
f cardiovascular disease, aspirin was shown to be effective
n reducing cardiovascular events in both women and men
9). However, women derived benefit from a reduction in
he risk of stroke, whereas men benefited by a reduction in
I. The increased (70%) risk of major bleeding from
spirin was similar between women and men (9). Another
lass of antiplatelet medication, the intravenous glyco-
rotein IIb/IIIa inhibitors, was noted to have a significant
esponse by sex. Men, and not women, were noted to have
significant reduction in cardiovascular events, although
his difference was largely attributed to patients’ baseline
the amount of data contributed by each trial. Abbreviations as in Figure 2.e
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November 17, 2009:1935–45 Clopidogrel and Sexo clinical study of clopidogrel in women and men,
espectively.
Clopidogrel, a nonreversible platelet antagonist, is a
econd-generation drug in the class of thienopyridines (35).
lthough clopidogrel is a more potent antiplatelet agent
han aspirin, both drugs have wide ranges of platelet
nhibition (36). Several studies have noted increased rates of
linical events among those with decreased platelet inhibi-
ion (hyporesponsiveness) to aspirin or clopidogrel (36–42).
n response, much attention is focused on identification of
hese groups with aspirin or clopidogrel hyporesponsiveness.
s has been reported with aspirin (43–45), women are also
ore often found to be hyporesponsive to clopidogrel (24).
owever, the clinical implication of these findings is
ncertain.
The current study shows that both women and men
enefit from clopidogrel across a wide spectrum of vascular
Figure 6 Effect of Clopidogrel Treatment on the Effect of Major
Pooled ORs are from a random-effects model. Sizes of data markers are proportio
andom-Effects ORs (95% CIs) for Clopidogrel Therapy Versus PlacTable 3 Random-Effects ORs (95% CIs) for Clopidogrel Therapy
Major Cardiovascular Event All-Cause Morta
Enrollment for ACS
Women 0.93 (0.85–1.01) 0.99 (0.90–1.0
Men 0.83 (0.74–0.93) 0.89 (0.82–0.9
Established CVD
Women 0.93 (0.85–1.01) 0.98 (0.89–1.0
Men 0.84 (0.78–0.92) 0.90 (0.83–0.9CS  acute coronary syndromes; CI  confidence interval; CVD  cardiovascular disease; OR  odds raisease and clinical presentations. The lack of significant
eterogeneity between women and men in their response to
lopidogrel for the primary end point and each individual
omponent reinforces this finding. Furthermore, both
omen and men are at risk for major bleeding from
lopidogrel when compared with placebo. Consistent with
rior studies (46–49), a numerically increased risk of major
leeding was found among women compared with men;
evertheless, no statistically significant difference existed
etween the sexes. However, with a greater emphasis being
laced on bleeding and its consequences (50), this finding is
mportant and may affect future drug development.
tudy limitations. First, as in most meta-analyses, these
esults should be incorporated with caution because the
nitial loading dose of clopidogrel and duration of treatment
ere not uniform. Importantly, these differences did not
esult in any statistically significant differences in the size of
ding
the amount of data contributed by each trial. Abbreviations as in Figure 2.
in Subgroup Analysesus Placebo in Subgroup Analyses
Myocardial Infarction Stroke Major Bleeding
0.80 (0.68–0.94) 0.80 (0.45–1.45) 1.50 (1.14–1.97)
0.82 (0.73–0.91) 0.83 (0.68–1.00) 1.18 (0.96–1.44)
0.81 (0.70–0.94) 0.92 (0.67–1.27) 1.43 (1.14–1.79)
0.82 (0.74–0.90) 0.81 (0.69–0.94) 1.19 (1.02–1.40)Blee
nal toeboVers
lity
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Clopidogrel and Sex November 17, 2009:1935–45he treatment effect between the trials. Furthermore, after
emoval of the largest trial with the shortest duration of
ollow-up (the COMMIT trial), the results obtained were
early identical. Second, we were unable to determine what
ffect clopidogrel has on particular subgroups of interest.
nly an analysis of patient-level data from all of the trials
ould allow an examination of the benefits of clopidogrel in
articular subgroups. Third, among the 5 trials, 4 different
efinitions of major bleeding were used. Although this
hould not change the conclusion of the results, these
ariations in major bleeding definitions make it impossible
o determine the true frequency of bleeding using any one of
he definitions. Fourth, although no significant differences
n benefit or risk from clopidogrel between men and women
ere observed on heterogeneity analyses, the benefit and
isk of clopidogrel was not perfectly homogenous in women
nd men, and we are unable to rule out with certainty that
ome difference in benefit and risk might exist. Finally,
eta-analysis remains retrospective research that is subject
o the methodological deficiencies of the included studies.
e minimized the likelihood of bias by developing a
etailed protocol before initiating the study, by performing
meticulous search for published and unpublished studies,
nd by using explicit methods for study selection, data
xtraction, and data analysis.
onclusions
his meta-analysis of more than 23,000 women and 56,000
en shows that clopidogrel is effective in reducing cardio-
stimated Number Needed to Treat or Harm Withlopidogrel Versus Placebo in S x-Stratifiednalysis for Each Indivi ual End Point Analyzed
Table 4
stimated N mber Needed to Tr at or Harm With
Clopidogrel Versus Placebo in Sex-Stratified
Analysis for Each Individual End Point Analyzed
Clopidogrel
(%)
Placebo
(%)
Change in
Absolute Risk
(%)
NNT or
NNH
MACE
Men 7.78 8.99 1.21 83
Women 11.02 11.76 0.74 135
All-cause mortality
Men 5.44 5.996 0.52 192
Women 8.74 8.85 0.11 909
Myocardial infarction
Men 2.80 3.36 0.56 179
Women 2.92 3.59 0.67 149
Stroke
Men 1.19 1.44 0.25 400
Women 1.61 1.95 0.34 294
Major bleeding
Men 1.33 1.11 0.22 455
Women 1.67 1.16 0.51 196
MACE  major bleeding
Men 9.11 10.1 0.99 101
Women 12.69 12.92 0.23 435
ajor adverse cardiovascular event (MACE): myocardial infarction, stroke, or cardiovascular death.
NNH  number needed to harm; NNT  number needed to treat.ascular events, and this difference is not significantlyifferent between women and men. Whereas women de-
ived a majority of their cardiovascular benefit by reducing
he risk of MI, men had a significant reduction in the risk
f MI, stroke, and all-cause mortality. This benefit was
onsistent across the spectrum of patients with cardiovas-
ular disease and did not differ by clinical presentation.
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